Cell and Gene Therapy 03/04/2018 The UK is a Leader in Preclinical Cell and Gene Therapy Research The UK has a rich and diverse range of preclinical research and is setting the foundations for the therapies of the future. The CGT Catapult’s...
Cell and Gene Therapy 21/03/2018 WEBINAR SERIES: Funding, Commercialisation and Market Access for... This webinar series has been co-organised by Phacilitate and Biotech and Money/LSX
Cell and Gene Therapy 15/03/2018 Curing COGs with Automation Is automation the cure for the cost of goods pandemic?
Cell and Gene Therapy 14/03/2018 Improving Immuno-oncology Patient Response Rates Discover the four cornerstones of improving patient response rates. Combination therapies, precision medicine, trial design and regulatory...
Cell and Gene Therapy 07/03/2018 Increasing Access to Cell and Gene Therapies: The Potential of... Could outcome-based annuity payments, in which cell and gene therapies are paid for over-time as benefits materialise, increase patient access to...
Cell and Gene Therapy 05/03/2018 The ROI of Automation in Cell-based Therapy Bioprocessing and... Phacilitate and Biolacuna have produced a cutting-edge report, which includes the results, data and analysis of an industry-wide survey, plus...
Cell and Gene Therapy 19/02/2018 Part Five: Commercialisation The supply chain story concludes with a focus on commercialisation and scale-up
Cell and Gene Therapy 19/02/2018 Part Four: Cryopreservation This report provides a comprehensive guide to successfully investing in advanced therapies. It also outlines across six chapters each of the...
Cell and Gene Therapy 19/02/2018 Part Three: Transportation This five-part supply chain case study series continues with one of the transportation
Cell and Gene Therapy 19/02/2018 Part Two: Registration and Workflow Management The second step in the supply chain case study series is registration and workflow management
Cell and Gene Therapy 19/02/2018 Part One: Supply Chain Planning This five-part supply chain case study series begins with one of the most important factors in the success of your supply chain. Planning
Cell and Gene Therapy 15/02/2018 Viral Safety for ATMPS - Part One Pathogen safety is a crucial but sometimes overlooked aspect of the development of advanced therapy medicinal products
Cell and Gene Therapy 15/02/2018 Infographic: Your Guide to Investing in Advanced Therapies In order to successfully invest in and realise the potential of advanced therapies, several technical factors must be well understood and...
Cell and Gene Therapy 08/02/2018 Video: How to Deliver Innovative Immunotherapies to Patients in the... The infrastructure of delivering immuno-oncology therapies is equal in importance to the science. the industry must develop clear plans for...
Immuno-oncology 08/02/2018 Video: Striking the Balance Between Regulatory Opportunities and... A video interview with Peter Olaganju, Senior Technical Director at Bluebird Bio. With every new opportunity comes great challenges
